ERBB2 and non-small cell lung carcinoma: The phase I dose-escalation and dose-expansion study of T-DXd in patients with advanced HER2-expressing or HER2- mutant solid tumors included eighteen patients with NSCLC and included tumors with activating HER2 mutations or HER2 expression (defined by IHC ≥ 1+ or amplification by in-situ hybridization or next-generation sequencing)50.